Deutsch English Français

Contact

EP2427205

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2427205

EP2427205 - PAR2 AGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 29.07.2016 Database last updated on 25.09.2024
Most recent event Tooltip	29.07.2016	Application deemed to be withdrawn	published on 31.08.2016 [2016/35]
Applicant(s)	For all designated states INSERM - Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR
	For all designated states Institut National de la Recherche Agronomique (INRA) 47, rue de l'Université 75007 Paris / FR
	[N/P]
Former [2012/11]	For all designated states INSERM - Institut National de la Santé et de la Recherche Médicale 101, rue de Tolbiac 75013 Paris / FR
	For all designated states Institut National De La Recherche Agronomique (INRA) 47, Rue de l'Université 75007 Paris / FR
Inventor(s)	01 / VERGNOLLE, Nathalie INSERM U563 CHU Purpan Place du Docteur Baylac BP3028 F-31024 Toulouse Cedex 3 / FR
	02 / RITEAU, Béatrice Unité de Virologie et Immunologie Moléculaires Unité de Recherche 892 Institut National de la Recherche Agronomique Domaine de Vilvert F-78352 Jouy-en-Josas / FR
	[2012/11]
Representative(s)	Plasseraud IP 104 Rue de Richelieu CS92104 75080 Paris Cedex 02 / FR
	[N/P]
Former [2014/23]	Cabinet Plasseraud 52 rue de la Victoire 75009 Paris / FR
Former [2012/11]	Hirsch, Denise Marie Inserm-Transfert Industrial Property Department Biopark 7 rue Watt 75013 Paris / FR
Application number, filing date	10718157.0	03.05.2010
	WO2010EP55980
Priority number, date	EP20090305393	04.05.2009 Original published format: EP 09305393
	[2012/11]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2010128016
	Date:	11.11.2010
	Language:	EN
	[2010/45]
	Type:	A2 Application without search report
	No.:	EP2427205
	Date:	14.03.2012
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.11.2010 takes the place of the publication of the European patent application.
	[2012/11]
Search report(s)	International search report - published on:	EP	03.02.2011
Classification	IPC:	A61K38/08	[2012/11]
	CPC:	A61K38/08 (EP,US); A61P31/16 (EP)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/11]
Title	German:	PAR2-AGONISTEN ZUR VERWENDUNG BEI DER BEHANDLUNG ODER PRÄVENTION VON INFEKTIONEN MIT DEM GRIPPEVIRUS TYP A	[2012/11]
	English:	PAR2 AGONISTS FOR USE IN THE TREATMENT OR PREVENTION OF INFLUENZA VIRUS TYPE A INFECTIONS	[2012/11]
	French:	AGONISTES DU RÉCEPTEUR PAR2 UTILISÉS DANS LE TRAITEMENT OU LA PRÉVENTION DES INFECTIONS DU VIRUS DE LA GRIPPE A	[2012/11]
Entry into regional phase	28.11.2011	National basic fee paid
	28.11.2011	Designation fee(s) paid
	28.11.2011	Examination fee paid
Examination procedure	28.11.2011	Examination requested [2012/11]
	25.06.2012	Amendment by applicant (claims and/or description)
	30.03.2015	Despatch of a communication from the examining division (Time limit: M04)
	12.05.2015	Reply to a communication from the examining division
	10.11.2015	Despatch of a communication from the examining division (Time limit: M04)
	22.03.2016	Application deemed to be withdrawn, date of legal effect [2016/35]
	18.04.2016	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2016/35]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 30.03.2015
Fees paid	Renewal fee
	28.05.2012	Renewal fee patent year 03
	29.05.2013	Renewal fee patent year 04
	26.05.2014	Renewal fee patent year 05
	28.05.2015	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	31.05.2016	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[Y]WO03104268 (UNIV EDINBURGH [GB], et al) [Y] 3 * the whole document *;
		[XY] - FELD MICHA ET AL, "Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible effects on human monocytes: Role in influenza a infection", JOURNAL OF IMMUNOLOGY, (200805), vol. 180, no. 10, ISSN 0022-1767, pages 6903 - 6910, XP002610042 [X] 1,2 * the whole document * [Y] 3
		[A] - LAN ROMMEL S ET AL, "Modulation of airway smooth muscle tone by protease activated receptor-1,-2,-3 and -4 in trachea isolated from influenza A virus-infected mice", BRITISH JOURNAL OF PHARMACOLOGY, (200001), vol. 129, no. 1, ISSN 0007-1188, pages 63 - 70, XP002610043 [A] 3 * the whole document *
	Examination	- D TURNER ET AL, "Systematic review and economic decision modelling for the prevention and treatment of influenza A and B Executive summary The prevention and treatment of influenza A and B", HTA HEALTH TECHNOLOGY ASSESSMENT NHS R&D HTA PROGRAMME HEALTH TECHNOLOGY ASSESSMENT, (20030101), URL: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0015076/pdf/summ735.pdf, (20150309), XP055174954
	by applicant	- HOLLENBERG, M. D. ET AL., CAN. J. PHYSIOL. PHARMACOL., (1997), vol. 75, pages 832 - 841
		- KAWABATA, A. ET AL., J. PHARMACOL. EXP. THER., (1999), vol. 288, pages 358 - 370
		- HOWTHORNE ET AL., "A High-Throughput Microtiter Plate-Based Calcium Assay for the Study of Protease-Activated Receptor 2 Activation", ANALYTICAL BIOCHEMISTRY, (2001), vol. 290, pages 378 - 379
		- BARANY, PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 189 - 193
		- GUATELLI ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 57, pages 1874 - 1878
		- KWOH ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, pages 1173 - 1177
		- LIZARDI ET AL., BIOL. TECHNOLOGY, (1988), vol. 6, page 1197
		- ADRIAN CABESTRE, F.; P. MOREAU; B. RITEAU; E. C. IBRAHIM; C. LE DANFF; J. DAUSSET; N. ROUAS-FREISS; E. D. CAROSELLA; P. PAUL, "HLA-G expression in human melanoma cells: protection from NK cytolysis", J REPROD IMMUNOL., (1999), vol. 43, pages 183 - 193
		- BACH, E. A.; M. AGUET; R. D. SCHREIBER, "The IFN gamma receptor: a paradigm for cytokine receptor signaling", ANNU REV IMMUNOL., (1997), vol. 15, pages 563 - 5691
		- BERNARD, D.; B. RITEAU; J. D. HANSEN; R. B. PHILLIPS; F. MICHEL; P. BOUDINOT; A. BENMANSOUR, "Costimulatory receptors in a teleost fish: typical CD28, elusive CTLA4", J IMMUNOL., (2006), vol. 176, pages 4191 - 4200
		- CHIGNARD, M.; D. PIDARD., "Neutrophil and pathogen proteinases versus proteinase-activated receptor-2 lung epithelial cells: more terminators than activators", AM J RESPIR CELL MOL BIOL., (2006), vol. 34, pages 394 - 398
		- FELD, M.; V. M. SHPACOVITCH; C. EHRHARDT; C. KERKHOFF; M. D. HOLLENBERG; N. VERGNOLLE; S. LUDWIG; M. STEINHOFF, "Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible effects on human monocytes: role in influenza A infection", J IMMUNOL., (2008), vol. 180, pages 6903 - 6910, XP002610042
		- GARDELL LR; MA JN; SEITZBERG JG; KNAPP AE; SCHIFFER HH; TABATABAEI A; DAVIS CN; OWENS M; CLEMONS B; WONG KK, "Identification and characterization of novel small-molecule protease-activated receptor 2 agonists", J PHARMACOL EXP THER., (200812), vol. 327, no. 3, doi:doi:10.1124/jpet.108.142570, pages 799 - 808, XP055005360 DOI: http://dx.doi.org/10.1124/jpet.108.142570
		- GRAHAM, M. B.; D. K. DALTON; D. GILTINAN; V. L. BRACIALE; T. A. STEWART; T. J. BRACIALE, "Response to influenza infection in mice with a targeted disruption in the interferon gamma gene", J EXP MED., (1993), vol. 178, pages 1725 - 1732
		- LAN, R. S.; G. A. STEWART; R. G. GOLDIE; P. J. HENRY, "Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice", AM J PHYSIOL LUNG CELL MOL PHYSIOL., (2004), vol. 286, doi:doi:10.1152/ajplung.00286.2003, pages L388 - 398, XP002574093 DOI: http://dx.doi.org/10.1152/ajplung.00286.2003
		- LEBOUDER, F.; E. MORELLO; G. F. RIMMELZWAAN; F. BOSSE; C. PECHOUX; B. DELMAS; B. RITEAU, "Annexin II incorporated into influenza virus particles supports virus replication by converting plasminogen into plasmin", J VIROL., (2008), vol. 82, pages 6820 - 6828
		- PASCALE, F.; V. CONTRERAS; M. BONNEAU; A. COURBET; S. CHILMONCZYK; C. BEVILACQUA; M. EPARAUD; V. NIBORSKI; S. RIFFAULT; A. M. BALA, "Plasmacytoid dendritic cells migrate in afferent skin lymph", J IMMUNOL., (2008), vol. 180, pages 5963 - 5972
		- RAGE, F.; B. RITEAU; G. ALONSO; L. TAPIA-ARANCIBIA, "Brain-derived neurotrophic factor and neurotrophin-3 enhance somatostatin gene expression through a likely direct effect on hypothalamic somatostatin neurons", ENDOCRINOLOGY, (1999), vol. 140, pages 909 - 916
		- RITEAU, B.; C. DE VAUREIX; F. LEFEVRE, "Trypsin increases pseudorabies virus production through activation of the ERK signalling pathway", J GEN VIROL., (2006), vol. 87, pages 1109 - 1112
		- RITEAU, B.; D. F. BARBER; E. O. LONG, "Vavl phosphorylation is induced by beta2 integrin engagement on natural killer cells upstream of actin cytoskeleton and lipid raft reorganization", J EXP MED., (2003), vol. 198, pages 469 - 474
		- RITEAU, B.; F. FAURE; C. MENIER; S. VIEL; E. D. CAROSELLA; S. AMIGORENA; N. ROUAS-FREISS, "Exosomes bearing HLA-G are released by melanoma cells", HUM IMMUNOL., (2003), vol. 64, pages 1064 - 1072
		- RITEAU, B.; N. ROUAS-FREISS; C. MENIER; P. PAUL; J. DAUSSET; E. D. CAROSELLA, "HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface glycoproteins inhibit NK and antigen-specific CTL cytolysis", J IMMUNOL., (2001), vol. 166, pages 5018 - 5026
		- RITEAU, B.; P. MOREAU; C. MENIER; 1. KHALIL-DAHER; K. KHOSROTEHRANI; R. BRAS-GONCALVES; P. PAUL; J. DAUSSET; N. ROUAS-FREISS; E. D, "Characterization of HLA-Gl, -G2, -G3, and -G4 isoforms transfected in a human melanoma cell line", TRANSPLANT PROC., (2001), vol. 33, pages 2360 - 2364
		- STEINHOFF, M.; J. BUDDENKOTTE; V. SHPACOVITCH; A. RATTENHOLL; C. MOORMANN; N. VERGNOLLE; T. A. LUGER; M. D. HOLLENBERG, "Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response", ENDOCR REV., (2005), vol. 26, pages 1 - 43

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p